Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC) (SIRveNIB)
Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB)
Sponsor: National Cancer Centre, Singapore
This PHASE3 trial investigates Hepatocellular Carcinoma and is currently ongoing. National Cancer Centre, Singapore leads this study, which shows 8 recorded versions since 2010 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
-
May 2020 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jun 2018 — May 2020 [monthly]
Active Not Recruiting PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Jul 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Centre, Singapore
- National Medical Research Council (NMRC), Singapore
- Singapore Clinical Research Institute
- Singapore General Hospital
- Sirtex Medical
For direct contact, visit the study record on ClinicalTrials.gov .